

PRESCRIPTION MONOGRAPH

Compounded Active Ingredients: Minoxidil/Progesterone/Melatonin/Fluocinolone

Form: Topical Foam

Drug Class:

- Minoxidil: Antihypertensive vasodilator
 - Progesterone: Progestin (Natural Steroid Hormone); local 5- α -reductase modulator
 - Melatonin: Eurohormone/chronobiotic with antioxidant and follicular MT1/MT2 receptor activity
 - Fluocinolone: Corticosteroid
-

Mechanism of Action^{1,2,3,4}:

When compounded together, Minoxidil, Progesterone, Melatonin, and Fluocinolone have the potential to provide a multi-targeted approach that enhances overall hair growth and preservation. Together they are intended to:

- Stimulate vascular and follicular activity by opening potassium channels in dermal papilla cells, to enhance blood flow and nutrient delivery to follicles, promoting local growth factors.
 - Reduce the effect of androgens by blocking the 5- α -reductase enzyme in hair follicles, lowering scalp DHT and helping slow follicle shrinkage.
 - Counter oxidative/androgen stress by scavenging reactive oxygen species in scalp, modulating MT1/MT2 on follicles, and lowering androgen influence in targeted tissues to help potentially protect dermal papilla cells.
 - Control inflammation by dampening cytokine signaling, reducing perifollicular inflammation, and improving tolerability of other ingredients.
-

Indications Commonly Prescribed For:

- Androgenetic alopecia
 - Post-inflammatory shedding
 - Cosmetic hair quality: To improve density, thickness, and retention.
 - Inflammatory scalp alopecia
-

Before Use: Let your health care provider know if you have any medication allergies before you take this compounded preparation. Let your health care provider know if you have any liver or kidney problems. Let your healthcare provider know of all supplements you are currently taking.

Contraindications:

- Hypersensitivity to any component
 - Scalp irritation or dermatitis where barrier is compromised
 - Systemic absorption of high minoxidil concentrations may cause hypotension
-

Cautions: Let your Healthcare provider know if you experience any adverse side effects.

PRESCRIPTION MONOGRAPH

How to Use: This compounded preparation is provided as a topical foam for application to the scalp. Apply the directed amount of foam to the affected areas, usually once or twice daily as instructed by your provider. Part the hair to ensure the foam makes direct contact with the scalp and gently massage if recommended. Wash your hands thoroughly after application. Avoid contact with the eyes, mouth, or broken skin. If you miss a dose, take as soon as you remember, but not at the time for the next dose. Desired results may take up to 3-6 months; continuous use is needed to maintain effect.

Warnings and Precautions:

- Initial shedding: Minoxidil may cause early “shedding” as follicles transition.
 - Systemic absorption risk: monitor for hypotension and tachycardia.
 - Cumulative irritation with retinoids or acids may increase scalp sensitivity—stagger products.
 - Scalp conditions: Use with caution with psoriasis, eczema, or other compromised barrier.
 - Photosensitivity/photoprotection: Routine scalp photoprotection is sensible in AGA; melatonin is antioxidant but not a sunscreen.
 - Topical steroid risks include atrophy, telangiectasias, or rebound dermatitis with prolonged use.
-

Adverse Reactions:

Common:

- Mild skin irritation
- Transient erythema
- Itching, Dryness
- Initial shedding

Rare:

- Nausea, Dizziness
 - Tachycardia
 - Breast Tenderness
 - Hair atrophy
-

Interactions:

- Concurrent strong vasodilators or antihypertensives may have additive hypotensive effect if absorption is higher than expected.
 - Other active topicals (retinoids/strong acids/alcohol-heavy sprays) may increase irritation—stagger use.
 - May alter response if patient is on other hormonal therapies.
 - Corticosteroids: Local immunosuppression if used with other topical immunomodulators
-

Use in Specific Populations:

- Pregnancy: Avoid if pregnant or planning pregnancy due to teratogenic risk
 - Pediatrics: Avoid unless under dermatologic supervision.
 - Geriatrics: Start with the lower minoxidil strength (2%) and monitor tolerability.
-

Storage:

- Store in original container at room temperature (up to 30°C or 86°F)
 - Store in a cool dry place away from heat, sunlight, and moisture
-

PRESCRIPTION MONOGRAPH

Monitoring Parameters:

- Skin/hair response over 8–12 weeks
 - Safety/tolerability: ask about irritation, pruritus, scaling, systemic hormonal symptoms; adjust vehicle/strength or frequency as needed
 - Steroid use: Monitor for skin atrophy or telangiectasia if fluocinolone is used long term.
-

Citations:

1. Li M, Marubayashi A, Nakaya Y, Fukui K, Arase S. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. *J Invest Dermatol.* 2001;117(6):1594-1600. doi:10.1046/j.0022-202X.2001.01570.x
2. Tawanwongsri W, Eden C. Melatonin for hair regrowth: Preclinical insights, current evidence, and future perspectives. *Electron J Gen Med.* 2025;22(4):em669. doi:10.29333/ejgm/16520
3. Grymowicz M, Rudnicka E, Podfigurna A, Napierala P, Smolarczyk R, Smolarczyk K, Meczekalski B. Hormonal effects on hair follicles. *Int J Mol Sci.* 2020;21(15):5342. doi:10.3390/ijms21155342
4. Gregoire S, McIntosh B, Sanchez K, Biba U, Mostaghimi A. Local corticosteroids for alopecia areata: a narrative review. *Dermatology and Therapy.* 2025;15:1607–1631. doi:10.1007/s13555-025-01421-2